Peter Bialek

Peter joined Triplet Therapeutics, Inc. in 2018 as Head of Translational Sciences. He has worked in drug development for over 13 years, focusing on translational biology and biomarker strategies from early development into the clinic. His broad experience across multiple rare disease areas includes neuromuscular, pulmonary, neuroscience, blood and liver diseases. Most recently, Peter was Director of Translational Science at Intellia Therapeutics where he worked across therapeutic areas to investigate appropriate biomarker strategies for target engagement, disease mechanism and safety readouts. Previously, he worked at Proteostasis, RaNA Therapeutics and Pfizer. Peter received his PhD in Biochemistry from the University of Western Ontario, Canada.